Cyclacel Pharmaceuticals, Inc. Provides Update On Its Clinical Development Plan Of Sapacitabine For Myelodysplastic Syndromes (MDS)

Published: Jun 02, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BERKELEY HEIGHTS, N.J., May 31, 2014 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, announced plans for the clinical development of sapacitabine in a second potential indication for patients with myelodysplastic syndromes (MDS) after treatment failure of front-line hypomethylating agents.

Help employers find you! Check out all the jobs and post your resume.

Back to news